Deciphering Genomic Risk in Prostate Cancer—Ready for Prime Time
Menée à partir de pièces de résection provenant de 352 patients atteints d'un cancer de la prostate ayant récidivé après une prostatectomie radicale et traités par radiothérapie de sauvetage en combinaison ou non avec le bicatulamide (âge médian : 64,5 ans), cette étude évalue l'association entre les résultats du système de classification Decipher, basé sur l'expression de 22 gènes, et le risque de métastases distantes, la survie globale ainsi que la mortalité spécifique
Individualizing treatment recommendations for men with a diagnosis of prostate cancer remains a major challenge for clinicians. These challenges occupy many clinical scenarios ranging from newly diagnosed disease localized to the prostate to biochemically recurrent disease in the postprostatectomy setting, and in the distant metastatic settings. To date, clinical decision-making has largely rested on traditional clinicopathologic features, including Gleason grading, T stage, prostate-specific antigen (PSA) levels, margin status, lymph node involvement, and imaging. However, at best, these measures serve as incomplete surrogates for the actual underlying biology driving the behavior of the disease in each patient. Direct interrogation of biologic features of tumors (for example, in the form of gene expression assays) has been shown to provide superior prognostic accuracy over standard clinicopathologic features across several cancer types.
JAMA Oncology , éditorial, 2020